13.70

0.29% -0.04

After Hours: 13.70

Janux Therapeutics Inc (JANX)

Overview News Price History Option Chain Financials Discussions Forecast

Janux Therapeutics Inc stock is traded at $13.70, with a volume of 617.12K. It is down -0.29% in the last 24 hours and down -1.37% over the past month. Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Previous Close:

$13.74

Open:

$13.77

24h Volume:

617.12K

Relative Volume:

0.61

Market Cap:

$835.49M

Revenue:

$13.73M

Net Income/Loss:

$-114.48M

P/E Ratio:

-7.4384

EPS:

-1.8418

Net Cash Flow:

$-78.49M

1W Performance:

+0.59%

1M Performance:

-1.37%

6M Performance:

-6.48%

1Y Performance:

-41.97%

1-Day Range:

$13.63

$13.96

1-Week Range:

$12.98

$14.03

52-Week Range:

$12.12

$35.34

Janux Therapeutics Inc Stock (JANX) Company Profile

Name

Janux Therapeutics Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

(858) 751-4493

Address

10955 VISTA SORRENTO PARKWAY, SAN DIEGO

Employee

108

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

JANX's Discussions on Twitter

Compare JANX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JANX Janux Therapeutics Inc	13.70	837.93M	13.73M	-114.48M	-78.49M	-1.8418
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-20-26	Downgrade	Barclays	Overweight → Underweight
Apr-15-26	Downgrade	UBS	Buy → Neutral
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-17-25	Initiated	Barclays	Overweight
Sep-10-25	Initiated	Stifel	Buy
Sep-10-25	Initiated	Truist	Buy
Sep-04-25	Initiated	Guggenheim	Buy
Aug-19-25	Initiated	Piper Sandler	Overweight
Jul-11-25	Initiated	Raymond James	Outperform
Dec-03-24	Reiterated	BTIG Research	Buy
Dec-03-24	Reiterated	H.C. Wainwright	Buy
Nov-22-24	Initiated	Leerink Partners	Outperform
Oct-24-24	Initiated	UBS	Buy
Sep-06-24	Initiated	Stifel	Buy
May-30-24	Initiated	Scotiabank	Sector Perform
Mar-21-24	Initiated	BTIG Research	Buy
Mar-20-24	Initiated	Cantor Fitzgerald	Overweight
Apr-06-23	Initiated	Wedbush	Outperform
Nov-14-22	Initiated	William Blair	Outperform

View All

Janux Therapeutics Inc Stock (JANX) Latest News

Jun 16, 2026

Janux Therapeutics (JANX) details RSU and stock option grants to RA Capital–linked entities - Stock Titan

Jun 12, 2026

Janux Therapeutics (JANX) director reports RSU and option awards tied to RA Capital - Stock Titan

Jun 12, 2026

Janux Therapeutics (JANX) awards director RSUs and 15,500 options - Stock Titan

Jun 12, 2026

Janux Therapeutics (JANX) director awarded RSUs and stock options - Stock Titan

Jun 12, 2026

Director at Janux Therapeutics (JANX) gets new RSUs and stock options - Stock Titan

Jun 12, 2026

Janux Therapeutics Reports Results of 2026 Annual Meeting - TipRanks

Jun 12, 2026

Shareholders back Janux Therapeutics (NASDAQ: JANX) board and pay - Stock Titan

Jun 12, 2026

Jun 11, 2026